Valneva shares surge 13.81% after-hours as Q3 EPS of -$0.31 beats estimates by $0.02 despite revenue shortfall.

think> Okay, let's tackle this query step by step. The user wants me to act as a financial analyst explaining Valneva's stock price movement based on recent news. The stock went up 13.81% after-hours. I need to check the provided news events to see which ones are relevant and caused this movement. First, looking at the stock performance: Valneva's after-hours price increased by about 13.8%. The recent news includes several points. Let's go through each reason. Reason 1: Valneva's Q3 EPS was better than expected (-0.31 vs. -0.33), but revenue was below estimates. The stock closed at $9.23, down 19.95% in 3 months but up 98% in 12 months. This is a mixed result—EPS beat but revenue miss. The stock's performance in the last 3 months is down, but it's up over the year. This might not directly explain the after-hours surge unless there's more context. Reason 2: Shares face potential loss doubling. Analysts predict per-share loss could double compared to last year. This seems bearish, but the stock went up, so maybe this is conflicting. Reason 3: From the German article, Valneva had a revenue drop in Q3, but positive results for the Lyme vaccine were overlooked. The stock had a slight recovery but is still below the high. The article mentions that the market is confused because the official Q3 report is scheduled for Nov 20. The FDA had already delayed the Chikungunya vaccine, leading to a previous drop. The stock is in a weak position but has some positive news. Reason 4: Another German article states that Valneva expects a 100% increase in Q3 loss and revenue decline. The stock is under pressure, and the market is waiting for the official report. This is bearish, but again, the stock went up. Reason 5: French article mentions a 5.69% rise over seven days and 77% in a year. Recent day's close was down 2.52%. This seems like general performance but doesn't directly link to the after-hours surge. Reason 6: Multiple news items, including FDA delaying the Chikungunya vaccine (Ixchiq) in August, leading to a crash. Also, some buy ratings from analysts. The recent news includes a positive Zika vaccine trial in November with 93% seroconversion rates, which was a positive but not well-received due to financial concerns. There's also a mention of a potential buy recommendation from First Berlin Equity Research. Now, the after-hours surge is 13.8%, which is significant. The key is to find what caused this. The recent news includes the positive Zika vaccine results in November, which were mentioned in Reason 3 and 4. The Phase 1 trial for VLA1601 showed improved seroconversion rates. However, the market initially overlooked it due to the revenue miss and loss expectations. But maybe after the official Q3 report was delayed or some new info came out. Wait, the user's input says the stock is up after-hours, but the news events are from various dates, including the Q3 report scheduled for Nov 20. The user's input doesn't mention a new event after Nov 20. Wait, the current date in the example is 2025, but the user's input doesn't specify the exact date of the after-hours movement. Assuming the after-hours movement is after the Q3 report was released. Wait, no, the Q3 report is scheduled for Nov 20. If the after-hours movement is after that date, then maybe the report had positive elements. But in the provided news, the Q3 results were a revenue miss and EPS beat. The stock closed at $9.23, which is down 19.95% in 3 months but up 98% in 12 months. The after-hours surge might be due to the EPS beat despite the revenue miss. However, the after-hours movement is a surge, so maybe there's a positive catalyst not listed in the news. Alternatively, maybe the after-hours movement is due to the positive vaccine news mentioned in Reason 3 and 4, which were overlooked before but now getting attention. The user's input includes the news that Valneva announced encouraging Phase 1 trial results for the Zika vaccine in November, which could be the reason for the after-hours surge. However, the news in Reason 3 and 4 mention that the positive vaccine results were overlooked due to the revenue miss. But perhaps after the Q3 report was released, the market re-evaluated and reacted positively to the vaccine news. Alternatively, maybe the after-hours movement is due to the EPS beat, which is a positive factor. However.